Every material Form 8-K Amneal Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amneal reported third-quarter 2025 net revenue of $785 million, up 12% from $702 million a year earlier, and GAAP net income attributable to the company of $2 million, or $0.01 per diluted share, compared with a loss in the prior-year quarter. The company raised its 2025 adjusted EBITDA, adjusted diluted EPS and operating cash flow guidance and left net revenue guidance unchanged, while a $31.4 million loss on refinancing weighed on quarterly results.
Net revenue was $785 million, up 12%; Specialty rose 8%, Affordable Medicines rose 8% and AvKARE rose 24%.
GAAP net income attributable to Amneal was $2 million ($0.01 per diluted share); adjusted diluted EPS was $0.17, up 6% from $0.16.
2025 adjusted diluted EPS guidance was raised to $0.75-$0.80 from $0.70-$0.75, and adjusted EBITDA guidance to $675-$685 million from $665-$685 million.
The quarter included a $31.4 million loss on refinancing tied to the August 1, 2025 borrowing of $2.1 billion in term loans and $600 million of senior notes due 2032.
Amneal Pharmaceuticals reported second-quarter 2025 net revenue of $725 million, up 3% from a year earlier, and GAAP net income attributable to the company of $22 million, up from $6 million. The company raised its full-year 2025 adjusted EBITDA and adjusted diluted EPS guidance, while keeping net revenue guidance unchanged, and completed a debt refinancing that it says extends maturities to 2032.
Q2 2025 net revenue was $725 million, up 3% from $702 million; GAAP diluted EPS was $0.07 versus $0.02, and adjusted diluted EPS was $0.25, up 56%.
Adjusted EBITDA was $184 million, up 13% from the second quarter of 2024.
2025 guidance: adjusted EBITDA raised to $665 million-$685 million from $650 million-$675 million; adjusted diluted EPS raised to $0.70-$0.75 from $0.65-$0.70; net revenue unchanged at $3.0 billion-$3.1 billion.
On August 1, 2025, the company completed $2.1 billion of new seven-year Term B loans and $600 million of 6.875% senior secured notes due 2032, used to refinance prior debt.
On August 1, 2025, Amneal Pharmaceuticals LLC borrowed $2.1 billion of new seven-year term loans and completed a $600 million offering of 6.875% senior secured notes due 2032. The company used the proceeds to refinance its existing term loans, which had about $2.26 billion outstanding, and to repay its ABL facility in full. The filing describes a refinancing that replaces existing debt and extends maturities rather than adding a stated new use of cash.
New $2.1 billion term loan matures August 1, 2032, with interest at term SOFR plus a 3.50% margin
$600 million of 6.875% senior secured notes due August 1, 2032, issued at 100% of principal amount
Existing term loan of about $2.26 billion refinanced in full; ABL facility repaid and its maturity extended to August 1, 2030 with $600 million of commitments
Amneal Pharmaceuticals released unaudited preliminary second-quarter 2025 results, with net revenue of $720 million to $730 million and adjusted EBITDA of $180 million to $185 million, both up versus the same period in 2024. The company said it expects to meet or exceed its full-year 2025 guidance, and the figures may change before the final results due August 5, 2025. Separately, director Emily Peterson Alva resigned from the Board and its Audit Committee, effective immediately, which the company said was not due to any disagreement.
Net revenue of $720 million to $730 million, up about 3% from the same period in 2024
Adjusted EBITDA of $180 million to $185 million, up about 13%; income before income taxes of $45 million to $56 million versus $20 million a year earlier
Gross leverage fell to 3.8x and net leverage to 3.7x as of June 30, 2025, from 4.1x and 3.9x at December 31, 2024
Emily Peterson Alva, an Amneal Group designee, resigned from the Board on July 16, 2025; the Amneal Group's board designation right was reduced from six to five
Amneal Pharmaceuticals reported first-quarter 2025 net revenue of $695 million, up 5% from $659 million a year earlier, and net income attributable to the company of $12 million, compared with a net loss of $92 million in the first quarter of 2024. The company reaffirmed its full-year 2025 guidance, including net revenue of $3.0 billion to $3.1 billion and adjusted diluted EPS of $0.65 to $0.70, so shareholders see improved results with no change to the outlook.
Net revenue $695 million, up 5% from $659 million; Affordable Medicines up 6%, Specialty up 3%, AvKARE up 6%
GAAP diluted EPS $0.04 versus a loss of $0.30; adjusted diluted EPS $0.21, up 50% from $0.14
Adjusted EBITDA $170 million, up 12% from the prior-year quarter
Full-year 2025 guidance affirmed: adjusted EBITDA $650 million to $675 million; conference call at 8:30 am Eastern on May 2, 2025
Amneal Pharmaceuticals entered into an employment agreement with Jason Daly, its Chief Legal Officer and Corporate Secretary, effective March 1, 2025, which sets his title as Executive Vice President, Chief Legal Officer & Corporate Secretary. The agreement covers a $575,000 base salary, a target bonus of 55% of base salary, and severance terms that include enhanced protections tied to a change in control.
Annual base salary of $575,000, effective March 1, 2025
Target annual bonus equal to 55% of base salary, with a personal performance multiplier of zero to 150% of that amount
Severance on termination without cause or for good reason: 150% of base salary, prorated bonus, 18 months of benefits continuation and 12 months of outplacement assistance
Initial term runs until March 31, 2027, with automatic one-year renewals absent 90 days' notice of non-renewal
Amneal reported fourth-quarter and full-year 2024 results on February 28, 2025. Net revenue rose 18% in the quarter and 17% for the year, while the GAAP net loss narrowed in the quarter but widened for the full year, and adjusted diluted EPS declined. The company also gave 2025 guidance for net revenue of $3.0 billion to $3.1 billion and adjusted EBITDA of $650 million to $675 million.
Q4 2024 net revenue was $731 million, up 18% from $617 million; GAAP net loss attributable to Amneal was $31 million, versus $99 million in Q4 2023.
Q4 2024 adjusted diluted EPS was $0.12, compared with $0.14 in Q4 2023.
Full-year 2024 net revenue was $2.79 billion, up 17%; GAAP net loss was $117 million, versus $84 million in 2023; adjusted diluted EPS was $0.58, down 9%.
2025 guidance: net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $650 million to $675 million, and adjusted diluted EPS of $0.65 to $0.70.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amneal Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →